Articles related to FDA

Stay informed with the FDA’s latest update on temozolomide labeling, which includes new indications and safety guidelines crucial for treating specific brain tumors.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

Discover how Elrexfio’s conditional FDA approval could redefine the treatment landscape for patients with difficult-to-treat multiple myeloma. Dive into the promising clinical trial results and understand its potential impact on your practice.

Discover how AOC 1044’s recent FDA orphan drug designation could revolutionize the treatment landscape for Duchenne muscular dystrophy patients with exon 44 mutations. Stay tuned for upcoming results from the EXPLORE44 trial.

The FDA’s recent decision allows Fulcrum Therapeutics to continue its Phase 1b trial of FTX-6058, an oral therapy for SCD. The trial aims to explore the drug’s potential in increasing fetal hemoglobin levels, offering a new avenue for treatment.

Xdemvy, backed by robust clinical trials, offers a new, targeted treatment option for Demodex blepharitis. The FDA-approved solution is expected to be available by the end of August 2023.